Apogee Therapeutics, Inc. (APGE) FinancialsAPGEApogee Therapeutics, Inc.

Evaluating the bottom line, Apogee Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -32.46%, provide a clear picture of how effectively APGE converts its operational activities into shareholder value.

In the context of the broader market, APGE competes directly with industry leaders such as KRYS and AXSM. With a market capitalization of $10.22B, it holds a significant position in the sector. When comparing efficiency, APGE's gross margin of N/A stands against KRYS's 94.60% and AXSM's 93.06%. Such benchmarking helps identify whether Apogee Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has been experiencing significant net losses, with the latest quarterly net income reported at -$85,854,000. The forward P/E ratio is currently at 0, indicating no earnings expected in the near term, which is concerning for long-term investors.